Cancer Cell

Article	Citations
Molecular subtyping in urothelial carcinoma treatment	1426
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity	754
Spark in the darkness: Discovering action potentials in brain tumors	489
Advances in liquid biopsy: From exploration to practical application	484
Simplifying clinical use of TCGA molecular subtypes through machine learning models	450
Global alliances in translational cancer research	425
Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia	386
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance	380
Circular RNAs drive oncogenic chromosomal translocations within the MLL recombinome in leukemia	363
KIT as a therapeutic target in neuroendocrine prostate cancer	350
Stem-cell-like T cells have a specific entry gate to the tumor	341
Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development	319
Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology	311
Breaching B cell tolerance in the tumor microenvironment	309
Paradoxical cancer cell stimulation by IFNγ drives tumor hyperprogression upon checkpoint blockade immunotherapy	303
Tissue residency of memory CD8+ T cells matters in shaping immunogenicity of ovarian cancer	302
Japan’s conditional early approval program for innovative cancer drugs: Comparison of the regulatory processes with the US FDA and the EMA	290
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies	286
Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone	263
Elimination of fluorescent protein immunogenicity permits modeling of metastasis in immune-competent settings	260
STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma	256
Evolutionary switch in expression of key markers between mouse and human leads to mis-assignment of cell types in developing adrenal medulla	247
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC	244
Bacteria and fungi: The counteracting modulators of immune responses to radiation therapy in cancer	243
Plasma cell and cancer stem cell crosstalk in glioblastoma	241

Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy	238
Seed or soil: Tracing the immune subsets in metastatic tumors	231
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance	228
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity	227
Tracing back to one of the origins of immune evasion in pancreatic cancer	225
Immune pressure sculps tumor cells and trims high-quality mutations	223
Perilymphatic regulatory T cell-dendritic cell interactions represent a novel axis of immunosuppression in cancer	220
High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer	219
Patterns of immune equilibrium and escape in indolent and progressing tumors	217
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer	209
How to detect cancer early using cell-free DNA	209
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer	205
Resolving mutational signatures in cancer development	200
A rational targeted therapy for platinum-resistant small-cell lung cancer	200
Developing and validating model systems for immuno-oncology	199
Less, but better: A simplified design for T cell redirection and conditional payload delivery	198
Seeing the forest for the trees—single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer	197
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	196
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy	191
Oncogenic mutations drive intestinal cancer initiation through paracrine remodeling	188
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge	187
Decoding tumor microenvironments through artificial tumor transcriptomes	181
STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma	180
Deciphering the landscape of transcriptional heterogeneity across cancer	178
Mitochondrial control of antigen presentation in cancer cells	175
NEN in a dish: A patient-derived organoid biobank illuminates potential novel therapeutic opportunities for neuroendocrine neoplasms	174
From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space	174
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer	174
Transcription factor dependencies identify BAF-dependent cancers	172
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer	172
The KRAS mutational spectrum and its clinical implications in pancreatic cancer	171
IL-1 signaling in aging and cancer: An inflammaging feedback loop unveiled	170
Accelerated approvals: Early-phase success or premature authorization?	170
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion	169
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow	165
The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions	164
Cytokines in cancer	163
Genetic interactions reveal distinct biological and therapeutic implications in breast cancer	163
Cancer cell states: Lessons from ten years of single-cell RNA-sequencing of human tumors	159
Antihistamines for cancer immunotherapy: More than just treating allergies	158
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	157
Deep learning transforms colorectal cancer biomarker prediction from histopathology images	156
Characterization of the generic mutant p53-rescue compounds in a broad range of assays	156
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy	142
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer	141
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton	137
Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers	136
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy	134
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy	133
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial	131

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity	128
Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy	127
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance	127
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy	127
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	126
A temporal perspective for tumor-associated macrophage identities and functions	126
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity	125
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies	124
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies	123
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy	123
A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization	121
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition	121
Spatial profiling technologies illuminate the tumor microenvironment	121
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers	120
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer	120
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade	116
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function	115
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	113
Tumor organoids: Opportunities and challenges to guide precision medicine	113
Targeting APOBECs in cancer: It’s about timing	111
The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia	108
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms	107
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma	107
The discrete charm of oncolytic viruses: Toward the finish line	106
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	106
Thyroid hormone suppresses medulloblastoma progression through promoting terminal differentiation of tumor cells	106
Tumor microbiome links cellular programs and immunity in pancreatic cancer	104
Progress and potential: The Cancer Moonshot	103
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy	103
Proteogenomic and metabolomic characterization of human glioblastoma	102
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies	100
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling	100
Analyses of rare predisposing variants of lung cancer in 6,004 whole genomes in Chinese	100
Cholesterol atlas of tumor microenvironment provides route to improved CAR-T therapy	99
Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance	98
Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma	97
Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping	97
Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite	97
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas	97
B cells secrete GABA, which provokes a pro-tumor immune microenvironment	96
COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer	95
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations	94
PDGFRα+ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay	93
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients	93
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer	92
Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation	92
Dietary modulation of the gut microbiome as an immunoregulatory intervention	92
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer	90
Precision oncology across the ages: Impact on children, adolescents, and young adults	90
Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity	89
Detection and localization of early- and late-stage cancers using platelet RNA	89
Targeting pan-essential genes in cancer: Challenges and opportunities	89
New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening	89
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer	89
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies	88
Adiposity and sex-specific cancer risk	88
The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions	87
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer	87
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells	86
CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis	86
A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity	86
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies	86
Integrating minimal residual disease monitoring into clinical practice for NSCLC: Is the era upon us?	85
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	84
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma	84
A CDK4-selective inhibitor puts the brakes on cancer cells	83
Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer	82
Exploring the “chemo” in chemoimmunotherapy for triple-negative breast cancer	82
Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33	81
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma	81
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial	81
Metabolic engineering to facilitate anti-tumor immunity	80
Lineage tracing reveals metastatic dynamics	80
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer	79
Glucose makes Treg lose their temper	79
The mycobiome-immune axis: The next frontier in pancreatic cancer	78
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial	77
Adoptive cell transfer immunotherapy for patients with solid epithelial cancers	77
Human and machine: Better at pathology together?	77
Location of EGFR exon 20 insertions matters	76

Cancer microbiome	75
A STING operation to expose KRAS and STK11 co-mutated lung cancers	75
Subclonal mutations in epigenetic regulators bring fitness in times of stress	74
Unpacking circulating tumor DNA lends insight into prostate cancer biology and the clonal dynamics of metastasis	73
The aging lung microenvironment awakens melanoma metastases	73
B cell heterogeneity in cancer comes of age	72
Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche	71
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding	71
A pan-cancer single-cell RNA-seq atlas of intratumoral B cells	70
From intrinsic to adaptive clusters in breast cancer	68
Spatial oncology: Translating contextual biology to the clinic	68
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron	67
Boosting anticancer immunotherapy through androgen receptor blockade	67
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer	67
Cancer vaccines	66
Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets	66
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors	66
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial	66
Genomic mapping of metastatic organotropism in lung adenocarcinoma	65
T cell dynamism and immune-related adverse events	65
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation	63
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer	63
Identification of specific PP2A complexes involved in human cell transformation	63
Targeting brain macrophages: NF-κB as a therapeutic gateway in melanoma brain metastasis	62
Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer	62
Vascular characterization reveals immunomodulatory targets for brain metastases	60
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient	59
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer	59
Clonal hematopoiesis and differential outcomes after immune checkpoint blockade	59
When immunotherapy meets surgery in non-small cell lung cancer	58
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function	57
Stressing the importance of circadian time in treatment responses	57
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma	56
Virotherapy: The next addition to the standard of care for glioblastoma?	56
Patient-derived explants as tumor models	55
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma	54
Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth	52
A holistic view of cancer	52
How can we integrate the biology of breast cancer cell dormancy into clinical practice?	52
Immune cell triads reprogram exhausted CD8+ T cells for effective tumor elimination	51
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients	51
Bacteria in metastatic sites: Unveiling hidden players in cancer progression	51
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity	51
High endothelial venules in cancer: Regulation, function, and therapeutic implication	50
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients	50
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity	50
Technology meets TILs: Deciphering T cell function in the -omics era	50